<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660036</url>
  </required_header>
  <id_info>
    <org_study_id>07-154</org_study_id>
    <nct_id>NCT00660036</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the combination of gemtuzumab ozogamicin,&#xD;
      mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of mitoxantrone and etoposide is an active regimen in refractory/relapsed AML&#xD;
      patients. In order to improve the efficacy of mitoxantrone and etoposide as second line&#xD;
      therapy in patients with AML we proposed to conduct a phase I/II clinical trial combining&#xD;
      gemtuzumab ozogamicin with mitoxantrone and etoposide. The phase I portion of the trial will&#xD;
      determine the maximum tolerated dose of gemtuzumab ozogamicin combined with mitoxantrone and&#xD;
      etoposide and the phase II portion of the trial will determine the efficacy and safety of the&#xD;
      combined regimen in patients with AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to new safety information&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the toxicity and response rate of the combination therapy of mitoxantrone, etoposide and gemtuzumab ozogamicin as second line therapy in patients with acute myeloid leukemia (AML).</measure>
    <time_frame>Bone marrow biopsy and aspiration 14 days after gemtuzumab ozogamicin administration, to evaluate response to the study drug regimen.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the overall survival in patients with AML treated with the combination of mitoxantrone, etoposide and gemtuzumab ozogamicin.</measure>
    <time_frame>Indefinite; subjects are followed for survival.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Gemtuzumab ozogamicin/Mitoxantrone/Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab ozogamicin</intervention_name>
    <description>On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m^2, 6 mg/m^2 or 9 mg/m^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.</description>
    <arm_group_label>Gemtuzumab ozogamicin/Mitoxantrone/Etoposide</arm_group_label>
    <other_name>Mylotarg®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>On Days 1-3 of an inpatient hospital stay: 10 mg/m^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes</description>
    <arm_group_label>Gemtuzumab ozogamicin/Mitoxantrone/Etoposide</arm_group_label>
    <other_name>Novantrone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>On Days 1-5 of an inpatient hospital stay: 100 mg/m^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours</description>
    <arm_group_label>Gemtuzumab ozogamicin/Mitoxantrone/Etoposide</arm_group_label>
    <other_name>ToposarTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and have the ability to provide written consent&#xD;
&#xD;
          -  Between 18 and 70 years of age&#xD;
&#xD;
          -  Patients with CD33 positive (determined as CD33 expression in ≥ 20% of leukemic&#xD;
             blasts) de novo AML that did not respond to first line induction therapy&#xD;
&#xD;
          -  ECOG Performance Status of 0-2&#xD;
&#xD;
          -  Patients must have the following laboratory values within 48 hours prior to beginning&#xD;
             protocol treatment: Serum creatinine ≤ 1.5 mg/ml and calculated creatinine clearance ≥&#xD;
             50mL/min (using the Cockcroft-Gault equation); AST ≤ 59 IU/L; ALT ≤ 72 IU/L; Total&#xD;
             bilirubin ≤ 1.3 mg/ml; Note: Hematologic abnormalities will not be used as a criteria&#xD;
             for entry or exclusion.&#xD;
&#xD;
          -  Patients must have left ventricular ejection fraction (LVEF) ≥50%&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative pregnancy test during&#xD;
             screening and all subjects must agree to use an effective method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia&#xD;
&#xD;
          -  Prior use of mitoxantrone or etoposide or gemtuzumab ozogamicin&#xD;
&#xD;
          -  Antecedent hematologic disorder preceding initial presentation of AML or therapy&#xD;
             related AML&#xD;
&#xD;
          -  History of thromboembolic event within the past 12 months&#xD;
&#xD;
          -  Hepatitis B or C or HIV positive serology&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) involvement&#xD;
&#xD;
          -  History of congestive heart failure&#xD;
&#xD;
          -  Myocardial infarction in the past 6 months&#xD;
&#xD;
          -  Uncontrolled, life-threatening infection that is not responding to antimicrobial&#xD;
             therapy&#xD;
&#xD;
          -  History of psychiatric disorder which may compromise compliance with the protocol or&#xD;
             which does not allow for appropriate informed consent&#xD;
&#xD;
          -  Patient may not be receiving any other anti neoplastic investigational agents&#xD;
&#xD;
          -  INR&gt; 1.5 or patient is receiving systemic anticoagulation (e.g warfarin)&#xD;
&#xD;
          -  Patient undergone autologous or allogeneic stem cell transplantation&#xD;
&#xD;
          -  Other active malignancies except for non-melanoma skin cancer or cervical&#xD;
             intraepithelial neoplasia&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boyiadzis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute / Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Michael Boyiadzis</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Second line</keyword>
  <keyword>Gemtuzumab ozogamicin</keyword>
  <keyword>Mitoxantrone</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

